News | Radiation Therapy | August 02, 2019

Varian Showcases Cancer Care Systems and Software at AAPM 2019

Offerings highlighted by Identify guidance system for enhanced patient identification, positioning and motion management during surface-guided radiation therapy

Varian Showcases Cancer Care Systems and Software at AAPM 2019

August 2, 2019 — Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the recent American Association of Physicists in Medicine (AAPM) 2019 annual meeting, July 14-18  in San Antonio, Texas.

Identify is an automated patient identification, positioning and motion management system for radiation therapy. It incorporates patient safety, quality, efficiency and surface-guidance features in an automated workflow solution for surface-guided radiation therapy (SGRT). 

Other Varian solutions showcased bring together artificial intelligence (AI), data analytics, science and technology, and include:

  • RapidPlan leverages machine learning to help clinicians achieve greater treatment plan consistency, efficiency and quality;
  • Multi-Criteria Optimization (MCO) improves the efficiency and quality of treatment planning by helping clinicians explore clinical tradeoffs when they vary plan parameters;
  • Noona is an intuitive solution for patients to report on their symptoms and outcomes, enabling better symptom monitoring, proactive management, and patient triage; and
  • ProBeam 360° system, designed for next-generation proton therapy, offers high-level clinical capabilities, a 360-degree gantry and RapidScan technology, which simplifies the process of motion management by delivering each field in a single breath-hold

Also on display was the full spectrum of Varian software solutions for: brachytherapy treatment planning and guidance, practice management, radiosurgery delivery, machine quality assurance, imaging informatics, image-guided dosimetry for Y90 selective internal radiation therapy (SIRT), tumor board management and more.

For more information:

Related Content

The research evaluates the feasibility of biology-guided radiotherapy to treat metastatic cancer
News | Radiation Therapy | October 24, 2020
October 24, 2020 — ...
AI-powered premium large bore CT scanner offers industry’s largest bore and widest field-of-view
News | Computed Tomography (CT) | October 24, 2020
October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S.
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...
IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy
News | Proton Therapy | October 23, 2020
October 23, 2020 — IBA, a leading provider of proton thera...
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...
Recommendations address patient selection and treatment techniques for locally advanced disease

Getty Images

News | Radiation Therapy | October 22, 2020
October 22, 2020 — A new ...
On Oct. 21, Seema Verma, administrator of the Centers for Medicare & Medicaid Services, tweeted that CMS will delay the Radiation Oncology Model’s launch from Jan. 1 to July 1 

Getty Images

News | ASTRO | October 22, 2020
October 22, 2020 — In response to the Oct.
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...